Introduction
PrP Sc , which is the pathogenic isoform of normal cellular prion protein, termed PrP C , is a biochemical marker for the diagnosis of human and animal TSEs. TSEs include bovine spongiform encephalopathy (BSE) in cattle, variant Creutzfeldt-Jakob Disease (vCJD) in humans and scrapie in sheep. Diagnosis of TSEs can be accomplished by a variety of tests using monoclonal and polyclonal antibodies which identify PrP Sc .
Several recent studies report additional techniques for the detection of PrP Sc involving repeated sonication of PrP C in the presence of PrP Sc seed, protein misfolding cyclic amplification (PMCA) (1) and the identification of uPrP Sc in the urine of TSE-positive animals and humans (2) . Early diagnosis, therapy and prophylaxis of the TSEs are considered to be very important problems that confront the medical community.
Solutions to these problems will be advanced by understanding the details of the conversion of PrP C to PrP Sc , and the mechanisms involved in PrP Sc accumulation.
However, the posttranslational modifications involved in the conversion of the hostcoded glycoprotein into its pathogenic isoform are poorly understood.
Nonenzymatic glycation between reducing sugars and amino groups of proteins, termed the Maillard reaction, produces reversible Schiff bases and Amadori products.
These early glycated products undergo further complex and advanced glycation and oxidation (glycoxidation), which elicits irreversible modification, to form heteromorphic and fluorescent derivatives termed AGEs (3, 4) . AGEs can be synthesized in vitro by glycoxidation between reducing sugars, such as glucose [although compounds including glycolaldehyde, glyoxal and methylglyoxal are more reactive than glucose in vitro], and proteins such as bovine serum albumin (BSA), RNase, and collagen (5, 6) . Amino groups that are located in the side chains of amino acids, such as lysine and arginine, are primary targets for nonenzymatic glycoxidation with carbohydrates.
AGEs have been reported to be associated with pathogenesis in vascular disease, diabetes, atherosclerosis, renal failure, Alzheimer's disease (AD) and Parkinson's disease (PD), suggesting that AGEs may contribute to the progressive deterioration associated with these chronic diseases. Furthermore, the deleterious effects of AGEs may be associated with oxidative stress (7) (8) (9) (10) (11) (12) . It has been shown that tau, a protein associated with paired helical filaments (PHFs), which plays an important role in AD pathology, is advanced-glycated; AGE-positive immunostaining is present in the neuritic plaques and the neurofibrillary tangles (NFT) in AD brains (13) . In addition, ß 2 -microglobulin that is accumulated in amyloidosis and recombinant human interferon gamma produced in Escherichia coli are nonenzymatically glycated (14) (15) (16) . The formation of AGEs is irreversible and causes protease-resistant modification of these peptides and proteins, leading to their deposition and to amyloidosis (17) (18) (19) . These reports suggested an
Experimental Procedures
Animals and scrapie strains.
Inbred mice (C57BL/6J, MB) and golden Syrian hamsters (SHa), 6 weeks of age, were obtained from the Experimental Animal Center of Hallym University, and divided into age-matched controls and groups destined to be infected with specific scrapie strains. Dr.
Alan Dickinson of the Neuropathogenesis Unit (Edinburgh, Scotland) kindly provided the following scrapie strains: ME7 and 22L which were passaged in C57BL mice and 87V which was passaged in MB mice. The 139A strain obtained from Dr. Richard H.
Kimberlin of the Neuropathogenesis Unit (Edinburgh, Scotland) was passaged in C57 BL mice, and the 263K and 139H scrapie strains were passaged in hamsters. scrapie-infected mice at 287 d.p.i.. Animals were sacrificed when clinical signs of the disease were manifested. Animals were anesthetized with 16.5% urethane and then transcardially perfused with cold PBS followed by cold 4% paraformaldehyde in PBS for brain sections, whereas for the isolation of PrP Sc -enriched insoluble fraction, each scrapie brain and age-matched control were frozen without perfusion and stored in -70°C prior to use. Also, frozen portions of the temporal cortex of normal human and CJD brains, and the frontal cortex of vCJD brain were used for isolation of PrP Sc -enriched fractions.
Preparation of in vitro AGE products and production of anti-AGE antibody.
AGE-modified BSA (AGE-BSA), lysine-derived AGE (AGE-Lys), argininederived AGE (AGE-Arg), and the AGE-modification of PrP peptides (Table 1 ) were prepared as previously described (20) . Briefly, BSA, lysine, arginine (Sigma, USA), and PrP peptides were dissolved with D-glucose (Sigma, USA) in 0.5 M sodium phosphate buffer (pH 7.4). The solution was deoxygenated with nitrogen gas, and sterilized by ultrafiltration (0.45-µ filter, Nalgene, USA), and then incubated at 37°C for 7, 50 or 90 days, as noted in results. After incubation, the samples except for lysine-and argininederived AGE were dialyzed using three changes of 20 mM sodium phosphate buffer (pH 7.4) containing 0.15 M NaCl. The dialyzed samples and the D-glucose treated lysine and arginine samples were then lyophilized. Rabbits were immunized with AGE-BSA as reported, and R3 anti-AGE antiserum was subsequently collected and purified with affigel Protein A agarose (Bio-Rad, USA). Affinity-purified IgG was passed over a column of activated Sepharose 4B (Amersham Pharmacia, USA) coupled with BSA two times.
The non-adsorbed fractions were combined and then passed over a column of AGE-BSA-coupled Sepharose 4B using a modification of a previous report (20) . Anti-AGE IgG bound to AGE-BSA, which comes from what did not bind to BSA, was eluted with 0.1 M citric acid (pH 3.0) and then neutralized with 1.0 M Tris-HCl (pH 9.0). R3 anti-AGE antiserum and anti-AGE IgG purified from antiserum were used in the current study.
Isolation of PrP Sc -enriched insoluble fraction.
PrP Sc -enriched insoluble fraction was isolated as previously described (21) . Briefly, each normal and TSE brain was homogenized in Tris-buffered saline (TBS, pH 7.4), and then rehomogenized in TBS (pH 7.4) containing 20% N-lauroyl sarcosine (Sigma, USA), and then centrifuged. The supernatant was ultracentrifuged and the resulting pellet resuspended in TBS (pH 7.4) containing 10% NaCl and 0.1% myristyl sulfobetaine (SB3-14) prior to treatment with or without proteinase K (PK) (Sigma, USA). After the sample was ultracentrifuged again, it was resuspended with TBS (pH 7.4) containing 0.1% SB3-14. The supernatant of normal brain preparation after ultracentrifuge was used as PrP C -containing fraction. Total proteins were quantified by modified Lowry method (22) . Fig. 1 A, C, and E, each membrane was stripped with buffer (2 ml of 10% SDS, 420 µl of 1.5 M Tris (pH 6.7), 70 µl of mercaptoethanol, 7.5 ml of triple-distilled H 2 O). Next, membranes were blocked with blocking solution, and incubated with goat anti-rabbit or anti-mouse IgG conjugated with peroxidase, and developed with SuperSignal West Pico (Pierce, USA). These processes demonstrate both complete stripping and exclusion of endogenous peroxidase activity. Thereafter, membranes were reprobed with monoclonal 3F4 anti-PrP antibody (Fig. 1B) or polyclonal 78295 anti-PrP antibody ( Fig. 1D and F) . 
Immunohistochemistry.
Following perfusion, brains were immediately removed, cut into blocks, postfixed in 4% paraformaldehyde for 12 h at 4°C, rinsed with PBS, dehydrated with ethanol, and then embedded in paraffin (Oxford, USA). Coronal sections of the brains (6 µm thick)
were cut with a microtome. Immunohistochemical analysis was carried out using the ABC kit (Vector, CA) by a modification of the avidin-biotin-peroxidase method.
Briefly, sections of the brains were deparaffinized with xylene, hydrated with graded ethanol, and then treated with 0.3% hydrogen peroxide in methyl alcohol to block endogenous peroxidase. The sections were treated with PK (10 µg/ml, 10 min) to remove PrP C , exposed to 10% normal donkey serum for 1 hr, and then incubated with one of the followings: R3 anti-AGE antiserum (1:500), rabbit anti-glial fibrillary acidic protein 
Antibodies
Two different anti-AGE antibodies were used in this study: (1) rabbit polyclonal anti-AGE antibody against AGE-BSA, which was produced in this study (R3); (2) mouse monoclonal anti-AGE antibody raised against AGE-BSA (6D12, TransGenic Inc., Japan), which has been selected as AGE-HSA-positive and BSA-negative, and is termed CML-positive (20, 24) . Two different anti-PrP antibodies were used; mouse monoclonal anti-PrP antibody (3F4) (25) and rabbit polyclonal anti-PrP antibody (78295) (26) . Anti-GFAP antibody (Jackson Laboratories, USA) was used for GFAP in immunohistochemistry.
Results

AGE-modified proteins accumulate in TSE brains
We hypothesized that the long-lasting PrP Sc molecules would be the most likely material to assay for nonenzymatic glycation in the brains of TSE-infected animals. The anti-AGE-BSA antiserum was pre-adsorbed with BSA to ensure specific staining of AGE-modified protein. R3 anti-AGE antiserum raised against many different types of AGE epitopes reveals that AGE-modified proteins are at a high concentration in 263K and 139H scrapie-infected brains but not in controls (Fig. 1A) . After stripping the membrane of R3 anti-AGE antibodies, PrP Sc was detected with PrP Sc specific antibody and these bands were identical to those seen with the AGE-antibody immunostaining (Fig. 1B) . Following PK digestion, which removes approximately 90 amino acids from the amino-terminus of PrP Sc , there was no detectable R3 anti-AGE antibody immunostaining (Figs. 1A, B) . AGE-modified proteins were also detected in mouse brains infected with the 139A, ME7, 22L and 87V scrapie strains, and in the brains of CJD and vCJD patients; but in each case reactivity disappeared after PK digestion (Figs.
1C, E, 2A). However, PK-resistant prion isoforms were detected after PK digestion (Figs. 1D, F) . As indicated from the results with normal brain material, the presence of soluble PrP C does not contribute to the results obtained for the insoluble fraction found in TSE brains (Figs. 1, 2A ). In the vCJD preparation, the lightly stained band with the lowest molecular weight (Fig 2A, lane 5) probably represents a small fragment of one of the PrP Sc isoforms that has been modified with AGE. Preimmune serum did not detect AGE-modified proteins in PrP Sc -enriched fractions, nor did anti-AGE antiserum that had been preabsorbed with AGE-modified BSA. In contrast, preincubation of anti-AGE antiserum with BSA that had not been AGE-modified did not reduce AGE immunostaining to yield the same as Fig. 1A , C and E (data not shown). In addition, AGE-modified proteins were detected with 6D12 anti-AGE antibody in 263K-infected brain; there was minimal staining of an unknown protein with molecular weight of approximately 32 kDa in the brains of normal hamsters (Fig. 2B, lane 1 ). There were no immunoprecipitates obtained from control brain preparation supernatants containing soluble PrP C (Fig. 2E) . These results indicate that AGE-modified proteins accumulated only in TSE brains and are composed of protease-resistant PrP Sc .
PrP Sc is modified with AGE, but PrP C is not
Immunoprecipitation assays support the finding that PrP Sc is nonenzymatically glycated in brain, but PrP C is not glycated (Figs. 2C, D, E and F) . AGE-modified proteins were immunoprecipitated from 263K and 139H scrapie-infected brains, and then detected with 3F4 anti-PrP antibody (Fig. 2C) . Conversely, prion isoforms were immunoprecipitated with 3F4 antibody, and then detected with R3 anti-AGE antibody (Fig. 2D) . Soluble PrP C in supernatant, however, was not immunoprecipitated, indicating that PrP C is not modified with AGE (Fig. 2E) . PNGase F was used to treat the insoluble fraction to remove one or both of N-glycans of prion isoforms and then immunoprecipitated with 6D12 anti-AGE IgG. Deglycosylated isoform of AGEmodified prion proteins was detected with R3 anti-AGE antibody (Fig. 2F, lane 1 and 2) .
Moreover, three AGE-modified prion isoforms were found in PNGase F-untreated insoluble fraction after immunoprecipitation with 6D12 anti-AGE IgG (Fig. 2F, lane 3 (Figs. 3A,   B ). These results suggest that AGE-modification occurs post-conversion of PrP into the PrP Sc conformation, however, it should be kept in mind that the result could be a function of the relative sensitivities of the antibodies, rather than a reflection of the timing of events.
The issue of possible non-specific endogenous peroxidase activity yielding falsepositive staining was of some concern. In fact, using the ascorbate test for catalytic metals (Buettner, 1990 ) that could bind to PrP Sc and thereby produce endogenous peroxidase activity, we found that several buffers used (0. (Fig. 3A) , indicating that PrP Sc does not have endogenous peroxidase activity.
Thus, despite the presence of contaminating metals in some of the buffers used in these studies (Table 2) , there was no evidence that the PrP Sc assayed by Western blots contained endogenous peroxidase activity.
Characteristics of AGE modification of PrP Sc
There are several key points with regard to the appearance patterns of AGE-modified PrP Sc . First, in 263K-and 139H-infected hamsters, AGE-mediated modification occurs most in diglycosylated PrP Sc and least in nonglycosylated PrP Sc . In contrast, AGE modification is distributed differently in most scrapie strain-mouse strain combinations (Fig. 2F, lane 1 and 2 ).
Nonenzymatic AGE modification of PrP Sc occurs at the N-terminal Lys residue and may be at residue 37 Arg
We speculated that the AGE epitope(s) is within the residues 23-89 of prion protein because it was not detected in PK-digested fractions (Fig. 1) . In order to map the epitope(s) involved in AGE-modified PrP Sc , we nonenzymatically glycated PrP peptides occurring in the NH 2 -terminus, specifically PrP peptide 23-36 and PrP peptide 37-50 incubated for 50 days. As shown in Fig. 4A , in vitro glycoxidation produces R3-positive AGE-mediated modification of BSA molecules (Fig. 4A, lane 1) , and PrP peptide 23-36 molecules (Fig. 4A, lane 3 To determine the exact AGE epitope in the N-terminal region of AGE-modified PrP Sc , we synthesized a series of 14-mer PrP peptides, starting from Lys 23 and continuing to residue 37. These peptides were then incubated with D-glucose for 90 days (Table 1) .
AGE-modified PrP peptides were stained with coomassie brillant blue (Fig. 5A ) and a second gel was blotted with anti-AGE antibody R3 (Fig. 5B) . The levels of staining vary significantly (Fig. 5A) according to the composition of amino acids (Table 1) . AGE-Lys and AGE-Arg incubated for 50 days were also stained, but were not positively blotted with R3 antibody (Fig. 5B) . AGE-PrP peptides that started from 23 Lys (lane 1), 24 Lys (lane 2) and 26 Pro (lane 4) were strongly immunostained with R3 compared to AGEPrP peptides that started from 27 Lys (lane 5) and 37 Arg (lane 15) (Fig. 5B) . However, residue 25 which starts from Arg was not positively stained with R3 anti-AGE antibody (Fig. 5B, lane 3) . We obtained similar results using 6D12 antibody (data not shown), except that only R3 immunoreact with the peptide that starts with residue 37 (Fig. 5B peptides. The failure to obtain reactivity with peptide 3, which also contains lysine, suggests that either the epitope in AGE-modified peptide 3 was not conclusive to antibody reactivity or that the configuration of the peptide prevented AGE formation. The reactivity of the R3 antibody with peptide 15 argues that the arginine in that peptide was AGE-modified and that the configuration was immunoreactive. Competitive ELISA supports these results. The competitions corresponded to the level of immunoreactivity of R3 anti-AGE antibody to AGE-PrP peptides (Fig. 5D) , whereas non-AGE-modified PrP peptides did not compete with AGE-modified PrP Sc (Fig. 5C ).
AGEs localize in astrocytes in 263K and 87V scrapie-infected brain
Cellular localization of AGE-modified PrP Sc was evaluated by immunohistochemical methods. AGEs and GFAP were immunostained with their respective R3 anti-AGE (Fig.   6C ) and anti-GFAP (Fig. 6D) antibodies in the hippocampus of 263K scrapie-infected brain, whereas there was virtually no staining for either AGE-modified protein (Fig. 6A) or reactive astrocytes ( A notable aspect in the immunostainings for GFAP, AGEs and PrP Sc is that all of the GFAP-positive astrocytes are not AGE-positive, whereas it seems likely that most of AGE-positive astrocytes are PrP Sc -positive, intimating that AGEs may be an additive risk factor for prion replication or prion deposition ( Figs. 6E and F; G and H) .
Discussion
Although the roles of normal and disease-associated prion isoforms in the infection process remain unclear, their importance in the pathogenesis of TSEs has been well documented (30) (31) (32) .
The findings in the current study clearly indicate that PrP Sc is modified by AGEs, characterized in large part by CML. This modification was seen with all of the TSE examined: (1) four mouse-adapted scrapie strains (ME7, 139A, 22L and 87V); (2) two hamster-adapted scrapie strains (263K and 139H), and (3) (Fig. 4A, lanes 1 and 3, Fig. 5B, lanes 1, 2, 4, 5 and 15). In this regard, the modification by AGE may be responsible for the dimerization of PrP Sc and further polymerization (34) .
It has been shown previously that PrP Sc is first detected in astrocytes in scrapieinfected mice (35) . In the current study, AGE-modified PrP Sc was found in GFAP- (Fig. 7A) (35) . More experiments will be required to determine the role of PrP Sc glycation in the disease process. As indicated in methods, 3.75 µl of 0.1 M ascorbate stock solution was added to 3.0 ml of each solution to be tested. The levels of ascorbate autoxidation are shown by the percentage loss of absorbance at 15 min compared to the determination of initial
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